Hospital Nuestra Señora del Prado, Talavera de la Reina, Spain.
J Investig Allergol Clin Immunol. 2010;20(6):454-62.
The fast-dissolving grass allergy immunotherapy tablet (grass AIT), Grazax, has proven effective in grass pollen-induced rhinoconjunctivitis.
To investigate the immunological and cutaneous changes induced after a short course with grass AIT.
We performed a randomized, double-blind placebo-controlled trial with 78 patients randomly assigned to receive either grass AIT or placebo in a 2:1 ratio. Treatment lasted at least 8 weeks before the grass pollen season (GPS), and continued until the season finished. Specific immunoglobulin (Ig) G4, IgE, and IgE-blocking factor to Phleum pratense were measured at the beginning of the trial and at different intervals during treatment. Immediate and delayed skin tests with P pratense were also performed. Safety endpoints were defined in terms of adverse events reported.
A total of 75 patients completed the trial (50 active and 25 placebo). P pratense IgG4, IgE, and IgE-blocking factor in actively treated patients increased significantly from baseline to the start of the GPS compared to placebo (P > .001, P = .017, and P = .005, respectively). The immediate cutaneous response was reduced during therapy in actively treated subjects, whereas placebo-treated subjects showed a decrease only after the start of the GPS. The delayed response to the intradermal test in grass AIT-treated subjects diminished, although not in a significantly different way from the placebo-treated subjects.
Treatment with grass AIT for grass pollen allergic rhinoconjunctivitis induces immunological changes after only 1 month of treatment.
速溶草过敏免疫治疗片（草 AIT）已被证明可有效治疗草花粉引起的鼻结膜炎。
研究短期草 AIT 治疗后诱导的免疫学和皮肤变化。
我们进行了一项随机、双盲、安慰剂对照试验，将 78 例患者随机分为草 AIT 组和安慰剂组，比例为 2:1。治疗至少在草花粉季节（GPS）前 8 周开始，并持续到季节结束。在试验开始时和治疗期间的不同时间点测量特异性免疫球蛋白（Ig）G4、IgE 和 IgE 阻断因子对 Phleum pratense 的水平。还进行了 Phleum pratense 的即刻和迟发皮肤试验。安全性终点定义为报告的不良事件。
共有 75 例患者完成了试验（50 例活性治疗组，25 例安慰剂组）。与安慰剂相比，接受活性治疗的患者的 P pratense IgG4、IgE 和 IgE 阻断因子从基线到 GPS 开始时显著增加（P >.001、P =.017 和 P =.005）。在治疗过程中，接受活性治疗的患者的即刻皮肤反应降低，而安慰剂治疗的患者仅在 GPS 开始后才出现下降。接受草 AIT 治疗的患者的皮内试验迟发反应减弱，但与安慰剂治疗的患者相比，无明显差异。
治疗草花粉过敏引起的鼻结膜炎仅需 1 个月的草 AIT 治疗即可诱导免疫学变化。
